A brief introduction to China's new Drug Administration Law and its impact on medications for rare diseases

被引：5
|
作者：
Wang, Yueqiang [1 ]
Chen, Duo [1 ]
He, Jiangjiang [1 ,2 ]
机构：
[1] Shanghai Med Informat Ctr, Shanghai Hlth Dev Res Ctr, 1477 Beijing W Rd, Shanghai 200040, Peoples R China
[2] Fudan Univ, Sch Publ Hlth, Shanghai, Peoples R China
来源：
INTRACTABLE & RARE DISEASES RESEARCH | 2019年 / 8卷 / 04期
关键词：
Drug Administration Law; characteristics of legislation; implementation of the law; rare disease; orphan drug;
D O I：
10.5582/irdr.2019.01133
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The Drug Administration Law of the People's Republic of China (amended in August 2019) is a major piece of legislation governing drug administration in China. This law seeks to improve health legislation; to achieve this, it defines the concepts of fake drugs and inferior drugs and their differences, it emphasizes the regulation of reliability, it standardizes online drug sales, it encourages technological innovation, and it specifies legal liability and punishment through legislative amendments. The Drug Administration Law is characteristic of responsive legislation, and it guarantees a right to health for citizens. The law provides for priority review and approval of new drugs for diseases like rare diseases, it encourages the domestic manufacturing and development of new drugs for rare diseases, and it provides a firm legal basis for medications to treat rare diseases under the Healthy China strategy.
引用
收藏
页码：226 / 230
页数：5
相关论文
共 36 条
  • [21] Historical experiences on mass drug administration for malaria control and elimination, its challenges and China's experience: a narrative review
    Nadia, Julie
    Lu, Fangli
    [J]. ACTA TROPICA, 2022, 225
  • [22] Forum: Holly Brewer's "Creating a Common Law of Slavery for England and its New World Empire"-Introduction
    Rao, Gautham
    [J]. LAW AND HISTORY REVIEW, 2022, 40 (03) : 579 - 580
  • [23] The impact of China's zero markup drug policy on drug costs for managing Parkinson's disease and its complications: an interrupted time series analysis
    Wang, Ruilin
    Li, Xinya
    Gu, Xinchun
    Cai, Qian
    Wang, Yayong
    Yi, Zhan-Miao
    Chen, Li-Chia
    [J]. FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [24] Viet Nam Viet Nam's New Law on Fisheries in Force and its Impact on Licenses to Fish
    Vo Ngoc Diep
    [J]. ASIA-PACIFIC JOURNAL OF OCEAN LAW AND POLICY, 2019, 4 (01) : 114 - 121
  • [25] Essay Topic: A New Era for a Higher Level of Public Participation in the Administration of Environmental Law and Justice in the People's Republic of China
    Zhang, Xu
    [J]. ENVIRONMENTAL AND PLANNING LAW JOURNAL, 2020, 37 (02): : 282 - 298
  • [26] Predicted Impact of the Food and Drug Administration's Menu-Labeling Regulations on Restaurants in 4 New Jersey Cities
    Gruner, Jessie
    DeWeese, Robin S.
    Lorts, Cori
    Yedidia, Michael J.
    Ohri-Vachaspati, Punam
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2018, 108 (02) : 234 - 240
  • [27] RENEWED MASS DRUG ADMINISTRATION'S IMPACT ON LYMPHATIC FILARIASIS IN A POPULATION WITH LONG LASTING INSECTICIDAL BEDNETS IN PAPUA NEW GUINEA
    Tisch, Daniel J.
    Mancuso, Brooke
    Cheng, Yao-Chieh
    Satofan, Samson
    Suamani, James
    Pomat, Willie
    King, Christopher L.
    Kazura, James W.
    Zimmerman, Peter A.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 7 - 8
  • [28] Health outcomes coding trends in the US Food and Drug Administration's Sentinel System during transition to International Classification of Diseases-10 coding system: A brief review
    Ham, Young Hee
    Mendelsohn, Aaron B.
    Panozzo, Catherine A.
    Maro, Judith C.
    Brown, Jeffrey S.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (07) : 838 - 842
  • [29] The Interdisciplinary Stem Cell Institute's Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases
    Khan, Aisha
    Bellio, Michael A.
    Schulman, Ivonne H.
    Levi, Allan D.
    Longsomboon, Bangon
    Brooks, Adriana
    Valasaki, Krystalenia
    DiFede, Darcy L.
    Pujol, Marietsy V.
    Yavagal, Dileep R.
    Bates, Karen E.
    Si, Ming-Sing
    Kaushal, Sunjay
    Green, Barth A.
    Anderson, Kimberly D.
    Guest, James D.
    Burks, Stephen Shelby
    Silvera, Risset
    Santamaria, Andrea J.
    Lalwani, Anil
    Dietrich, W. Dalton
    Hare, Joshua M.
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [30] Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling
    Pokorney, Sean D.
    Shrader, Peter
    Thomas, Laine
    Fonarow, Gregg C.
    Kowey, Peter R.
    Singer, Daniel E.
    Ansell, Jack
    Gersh, Bernard J.
    Mahaffey, Kenneth W.
    Hylek, Elaine M.
    Go, Alan S.
    Piccini, Jonathan P.
    Peterson, Eric D.
    [J]. CIRCULATION, 2016, 134 (15) : 1122 - 1124
1234